Enterprise Value
-3.201M
Cash
10.39M
Avg Qtr Burn
-7.059M
Short % of Float
2.26%
Insider Ownership
43.04%
Institutional Own.
8.15%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis | Approved Quarterly sales | |
XEPI (ozenoxacin) Details Impetigo | Approved Quarterly sales | |
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis) | Approved Quarterly sales | |
Ameluz® Details Actinic keratosis | Phase 3 Data readout | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis, Acne | Phase 2 Data readout | |
Ameluz® - PDT (3 tubes) Details Actinic keratosis | Phase 1 Update |